GeneFerm Biotechnology Co Ltd (1796) — Cash Flow Reinvestment Rate
GeneFerm Biotechnology Co Ltd (1796) has a Cash Flow Reinvestment Rate of 8.19x as of June 2025, reinvesting NT$11.86 Million (capex NT$5.98 Million plus investments NT$-5.88 Million) from operating cash flow of NT$1.45 Million. Check 1796 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
GeneFerm Biotechnology Co Ltd Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for GeneFerm Biotechnology Co Ltd across 8 annual periods. Explore 1796 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for GeneFerm Biotechnology Co Ltd (2017–2024)
Year-by-year capital reinvestment analysis for GeneFerm Biotechnology Co Ltd. For live market cap and broader valuation context, see 1796 company net worth.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 5.63x | NT$45.53 Million | NT$8.09 Million | NT$22.70 Million | ▲ +654.1% |
| 2023 | 0.75x | NT$142.02 Million | NT$190.31 Million | NT$71.40 Million | ▼ -83.6% |
| 2022 | 4.56x | NT$558.75 Million | NT$122.43 Million | NT$278.42 Million | ▲ +76.1% |
| 2021 | 2.59x | NT$290.86 Million | NT$112.23 Million | NT$145.61 Million | ▼ -11.0% |
| 2020 | 2.91x | NT$164.36 Million | NT$56.42 Million | NT$82.32 Million | ▼ -60.9% |
| 2019 | 7.45x | NT$109.43 Million | NT$14.69 Million | NT$54.57 Million | ▲ +437.6% |
| 2018 | 1.39x | NT$58.39 Million | NT$42.14 Million | NT$28.81 Million | ▼ -24.0% |
| 2017 | 1.82x | NT$111.31 Million | NT$61.08 Million | NT$55.16 Million | — |